;

BABRAHAM RESEARCH CAMPUS

THE BABRAHAM RESEARCH CAMPUS REMAINS OPEN FOR TENANT COMPANIES AND THEIR KEY WORKERS. Visitors and deliveries are to be kept to a minimum and social distancing advice adhered too.  Updates on the Babraham Institute can be found here.

The Babraham Research Campus is considered to be one of the UK’s leading campus' to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the Babraham Institute. World class research and business come together to promote innovation and strengthen links between academia and the commercial world. The Babraham Research Campus is managed and developed by Babraham Bioscience Technologies Ltd (BBT).

Explore More

OVER 60
ORGANISATIONS ON SITE

COMMUNITY OF
1400 PEOPLE

CIRCA 300,000 SQ. FT.
LABORATORY & OFFICE
SPACE AVAILABLE

6 MILES FROM
CAMBRIDGE CENTRAL

START-UP MINDSET SCALE-UP CAPABILITY

Accelerate@Babraham

Provides support to the earliest stages of new life-science ventures, via easy-access laboratory and office space, combined with additional support programmes.

BABRAHAM RESEARCH CAMPUS IMPACT REPORT

In 2019, the Campus partners commissioned a report to evidence the impact the Campus has had on science, the economy and society. Click below to explore more.

Our Community

Babraham Research Campus is the location of choice to start and build life-science enterprises for over 60 bioscience organisations.

Lastest News & Opinion

Mission and Imperial College London Report Potent and Selective Probe for Deubiquitylating Enzyme UCHL1

Working in close collaboration, scientists from the Tate Group, Imperial College London, and drug discovery and development company, Mission Therapeutics, have discovered the first exquisitely selective probe for a deubiquitylating enzyme (DUB).

Clinical Data Validates BenevolentAI's AI Predicted Hypothesis For Baricitinib As A Potential Treatment For COVID-19

BenevolentAI today announced the publication of further experimental data in support of its AI-derived hypothesis for baricitinib as a potential treatment for COVID-19 in the Journal: EMBO Molecular Medicine.

Mission Raises $15m and Expands its Relationship with Pfizer

Mission Therapeutics today announced that it has raised $15m (£12m) in equity investment. The round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc.
Access to all our news and opinions

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;